Dutasteride Capsule
Product Images NDC 71205-039

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Dutasteride (NDC 71205-039). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dutasteride Structural Formula (Dutasteride Capsules 1)

Chemical structure of Dutasteride showing its molecular arrangement including multiple rings, hydrogen atoms, and trifluoromethyl groups.*

FDA Label Image

Figure 1. Aua-si Score* Change From Baseline (randomized, Double-blind, Placebo-controlled Studies Pooled) (Dutasteride Capsules 2)

A line graph showing mean change from baseline in AUCSL over 24 months of treatment. It compares two groups: Placebo and Dutasteride, with data points at 0, 1, 3, 6, 12, 18, and 24 months. The graph illustrates trends in treatment effect over time.*

FDA Label Image

Figure 2. Percent Of Subjects Developing Acute Urinary Retention Over A 24-month Period (randomized, Double-blind, Placebo-controlled Studies Pooled) (Dutasteride Capsules 3)

A line graph comparing the cumulative number of events per patient over 24 months of treatment between a Placebo Group and a Dutasteride Group. The x-axis represents months of treatment from 0 to 24, while the y-axis represents events per patient ranging from 0 to 6. The graph includes data on the number of events and patients at risk at multiple time points for each group.*

FDA Label Image

Figure 3. Percent Of Subjects Having Surgery For Benign Prostatic Hyperplasia Over A 24-month Period (randomized, Double-blind, Placebo-controlled Studies Pooled) (Dutasteride Capsules 4)

A cumulative incidence line graph comparing placebo and dutasteride groups over 24 months of treatment. The x-axis represents months of treatment (0 to 24), and the y-axis shows the cumulative number of reported patients. Two lines depict cumulative events for the placebo group and the dutasteride group, with a table below indicating cumulative event numbers and the number of patients at risk at several time points for both groups.*

FDA Label Image

Figure 4. Prostate Volume Percent Change From Baseline (randomized, Double-blind, Placebo-controlled Studies Pooled) (Dutasteride Capsules 5)

A bar graph depicting mean percent change from baseline over time in months of treatment, comparing placebo and Dutasteride groups. The x-axis represents months of treatment (0, 1, 3, 6, 12, 24) and the y-axis shows mean percent change from baseline. The graph includes sample sizes for placebo and Dutasteride groups at each time point.*

FDA Label Image

Figure 5. Qmax Change From Baseline (randomized, Double-blind, Placebo-controlled Studies Pooled) (Dutasteride Capsules 6)

A line graph depicting mean change from baseline in a measurement over 24 months of treatment. The x-axis represents months of treatment from 0 to 24, and the y-axis shows mean change from baseline in milliliters per second. Two lines compare the effects of Placebo and Dutasteride, with Dutasteride showing a greater increase over time.*

FDA Label Image

1968f777-figure-07 (Dutasteride Capsules 7)

Line graph showing mean change from baseline in an unspecified measure over 48 months of treatment comparing Dutasteride 0.5 mg, Tamsulosin 0.4 mg, and their combination. The x-axis represents months of treatment, and the y-axis shows mean change from baseline in unspecified units. Data points represent different participant groups with sample sizes listed.*

FDA Label Image

Figure 7. Qmax Change From Baseline (combat Study) (Dutasteride Capsules 8)

A line chart depicting the mean change from baseline in an unspecified measurement over 24 months of treatment. The x-axis represents months of treatment (0, 6, 12, 18, 24), and the y-axis shows mean change from baseline in mL/25. Three lines represent Dutasteride with tamsulosin, Dutasteride 0.5 mg, and tamsulosin 0.4 mg, showing different trends over time.*

FDA Label Image

71205-039-90 (Dutasteride Capsules 9)

ProficientRx label for Dutasteride 0.5 mg capsules in a quantity of 90 capsules. The label indicates each capsule is a yellow oblong soft gelatin containing 0.5 mg dutasteride, USP, imprinted with 'A 75'. It includes storage instructions, distributor information (Amneal Pharmaceuticals), and notes the product is relabeled by Proficient Rx LP, Thousand Oaks, CA. The label also shows NDC 71205-039-90 with placeholder lot and expiration data.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.